Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2024
Reporting Period: Specific event date (November 12, 2024). This filing does not cover a standard fiscal quarter or year but reports material definitive agreements and unregistered sales of equity securities.
Key Financial Metrics and Transaction Details
This filing details a private placement financing and related debt repayment activities rather than standard operating financial results (revenue, profit, or cash flow from operations are not reported in this document).
- Capital Raised: $130.0 million gross proceeds from the sale of 130,000 shares of Series A Convertible Preferred Stock.
- Debt Repayment: Approximately $62.5 million in principal and interest outstanding under the Term Loan Facility is expected to be prepaid in full on November 13, 2024.
- Stock Repurchase: Approximately $23.5 million of net proceeds will be used to repurchase 7,421,731 shares of Class A Common Stock from existing stockholders (including directors) at $3.1597 per share.
- Transaction Fees: A 4.0% cash fee paid to the placement agent (Truist Securities, Inc.) based on gross proceeds.
- Liquidity Covenant: The amended Credit Agreement requires the Company to maintain Liquidity of at least $100,000,000 immediately after giving effect to cash payments for conversion obligations.
Material Changes Versus Prior Period
The filing reports significant structural changes to the Company's capitalization and debt profile effective November 12, 2024:
- Debt Reduction: The Company is eliminating its Term Loan Facility (approx. $62.5 million) using proceeds from the new equity offering.
- Equity Structure: Issuance of Series A Convertible Preferred Stock with a liquidation preference of $1,000 per share (increasing to $1,500 per share in a change of control before November 12, 2026).
- Share Count: Reduction in outstanding Class A Common Stock due to the repurchase of 7.4 million shares from specific insiders.
- Board Composition: The Board size increased to twelve directors with the appointment of Garrett Lustig as a designee of the new Investors.
Guidance, Outlook, Risks, and Unusual Items
Use of Proceeds: Net proceeds will fund strategic growth, operating and commercial activities, clinical development, working capital, capital expenditures, debt repayment, and general corporate purposes.
Convertible Preferred Stock Terms:
- Dividends: 8.0% per annum, compounding, payable quarterly in kind or cash at the Company's election.
- Conversion: Initial conversion rate of 263.7358 shares of Common Stock per share of Preferred Stock (implied conversion price of $3.7917, a 20% premium to the 10-day VWAP).
- Ownership Limitations: Conversion is capped at 19.99% of outstanding Common Stock without shareholder approval. Excess conversion value may be paid in cash ("Cash-in-Lieu Payments") with 10% annual interest.
- Redemption: Investors have an optional redemption right after November 12, 2031.
Risks and Contingencies:
- Forward-Looking Statements: The Company cautions that actual results may differ due to reimbursement level changes, competition, technological obsolescence, and regulatory changes.
- Financial History: The Company notes it has incurred losses in current and prior periods and may incur losses in the future.
- Liquidity Constraints: Cash payments for conversion are subject to maintaining specific leverage ratios and a minimum liquidity threshold of $100 million.
Important Facts for Investor Verification
- Verify the closing of the $130 million private placement and the subsequent prepayment of the $62.5 million Term Loan.
- Confirm the execution of the stock repurchase agreements with directors Glenn H. Nussdorf, Alan Ades, and Albert Erani.
- Monitor the Company's ability to maintain the $100 million liquidity covenant required by the amended Credit Agreement.
- Review the Certificate of Designation for specific anti-dilution adjustments and voting rights attached to the Series A Convertible Preferred Stock.
- Check for future shareholder votes required to lift the 19.99% ownership limitation on the conversion of Preferred Stock.